These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1160 related articles for article (PubMed ID: 26988947)
1. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P; J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947 [TBL] [Abstract][Full Text] [Related]
2. Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry. Saltijeral A; Pérez de Isla L; Alonso R; Muñiz O; Díaz-Díaz JL; Fuentes F; Mata N; de Andrés R; Díaz-Soto G; Pastor J; Pinilla JM; Zambón D; Pinto X; Badimón L; Mata P; Rev Esp Cardiol (Engl Ed); 2017 Jun; 70(6):444-450. PubMed ID: 27913073 [TBL] [Abstract][Full Text] [Related]
3. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071 [TBL] [Abstract][Full Text] [Related]
4. Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis. Oh J; Lee CJ; Kim DI; Rhee MY; Lee BK; Ahn Y; Cho BR; Woo JT; Hur SH; Jeong JO; Jang Y; Lee SH Clin Cardiol; 2017 Dec; 40(12):1291-1296. PubMed ID: 29243274 [TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Mata N; Alonso R; Badimón L; Padró T; Fuentes F; Muñiz O; Perez-Jiménez F; López-Miranda J; Díaz JL; Vidal JI; Barba A; Piedecausa M; Sanchez JF; Irigoyen L; Guallar E; Ordovas JM; Mata P Lipids Health Dis; 2011 Jun; 10():94. PubMed ID: 21663647 [TBL] [Abstract][Full Text] [Related]
6. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study. Alonso R; Arroyo-Olivares R; Díaz-Díaz JL; Fuentes-Jiménez F; Arrieta F; de Andrés R; Gonzalez-Bustos P; Argueso R; Martin-Ordiales M; Martinez-Faedo C; Illán F; Saenz P; Donate JM; Sanchez Muñoz-Torrero JF; Martinez-Hervas S; Mata P Atherosclerosis; 2024 Jun; 393():117516. PubMed ID: 38523000 [TBL] [Abstract][Full Text] [Related]
7. Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice. Vohnout B; Fábryová Ľ; Klabník A; Kadurová M; Bálinth K; Kozárová M; Bugáňová I; Sirotiaková J; Rašlová K Atherosclerosis; 2018 Oct; 277():323-326. PubMed ID: 30270066 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733 [TBL] [Abstract][Full Text] [Related]
9. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. Menzin J; Aggarwal J; Boatman B; Yu J; Stern K; Harrison DJ; Patel JG J Manag Care Spec Pharm; 2017 Dec; 23(12):1270-1276. PubMed ID: 29172973 [TBL] [Abstract][Full Text] [Related]
10. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. Yamashita S; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S J Atheroscler Thromb; 2022 May; 29(5):608-638. PubMed ID: 33980760 [TBL] [Abstract][Full Text] [Related]
12. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Krempf M; Simpson RJ; Ramey DR; Brudi P; Giezek H; Tomassini JE; Lee R; Farnier M Lipids Health Dis; 2015 May; 14():45. PubMed ID: 25985907 [TBL] [Abstract][Full Text] [Related]
13. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. Pérez de Isla L; Arroyo-Olivares R; Muñiz-Grijalvo O; Diaz-Díaz JL; Zambón D; Fuentes F; Sánchez Muñoz-Torrero JF; Mediavilla JD; González-Estrada A; Miramontes-González JP; de Andrés R; Mauri M; Mosquera D; Cepeda JM; Suárez L; Barba-Romero MÁ; Argüeso R; Álvarez-Baños P; Michán A; Romero-Jiménez MJ; García-Cruces J; Padró T; Alonso R; Mata P J Clin Lipidol; 2019; 13(6):989-996. PubMed ID: 31706904 [TBL] [Abstract][Full Text] [Related]
14. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition? Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F; Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826 [TBL] [Abstract][Full Text] [Related]
15. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Elis A; Zhou R; Stein EA Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982 [TBL] [Abstract][Full Text] [Related]
16. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067 [TBL] [Abstract][Full Text] [Related]
17. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Miname MH; Santos RD Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498 [TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization. Zafrir B; Shapira C; Lavie G; Halon DA; Flugelman MY J Clin Lipidol; 2016; 10(6):1338-1343. PubMed ID: 27919350 [TBL] [Abstract][Full Text] [Related]
19. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom. Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487 [TBL] [Abstract][Full Text] [Related]
20. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]